MARKET

THTX

THTX

Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.450
-0.240
-8.92%
Closed 16:00 02/24 EST
OPEN
2.650
PREV CLOSE
2.690
HIGH
2.650
LOW
2.410
VOLUME
152.77K
TURNOVER
--
52 WEEK HIGH
7.14
52 WEEK LOW
2.450
MARKET CAP
188.54M
P/E (TTM)
-26.7176
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of THTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average THTX stock price target is 12.00 with a high estimate of 12.00 and a low estimate of 12.00.

EPS

THTX News

More
  • Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2019
  • GlobeNewswire · 6d ago
  • Theratech inks agreement to advance tesamorelin for NASH
  • Seeking Alpha - Article · 02/04 12:59
  • Theratechnologies Signs Agreements With Massachusetts General Hospital and Dr. Steven Grinspoon
  • GlobeNewswire · 02/04 12:30
  • The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx
  • Benzinga · 01/10 12:13

Industry

Pharmaceuticals
-3.28%
Pharmaceuticals & Medical Research
-2.80%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About THTX

Theratechnologies Inc is a Canada-based specialty pharmaceutical company. The Company addresses medical needs to promote healthy living for human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). Ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition.
More

Webull offers kinds of Theratechnologies Inc stock information, including NASDAQ:THTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, THTX stock news, and many more online research tools to help you make informed decisions.